Cytosorbents Corp (OTCMKTS:CTSO) has been assigned a $12.00 target price by stock analysts at HC Wainwright in a report released on Tuesday. The firm presently has a a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 101.68% from the stock’s current price.

CTSO has been the subject of a number of other research reports. Maxim Group reiterated a “buy” rating on shares of Cytosorbents Corp in a report on Wednesday, June 15th. B. Riley initiated coverage on Cytosorbents Corp in a report on Thursday. They set a “buy” rating and a $11.25 target price for the company. Finally, Brean Capital initiated coverage on shares of Cytosorbents Corp in a research note on Tuesday, October 4th. They set a “buy” rating and a $24.00 price objective for the company. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $13.65.

Analyst Recommendations for Cytosorbents Corp (OTCMKTS:CTSO)

Shares of Cytosorbents Corp (OTCMKTS:CTSO) traded up 1.261% during trading on Tuesday, reaching $6.025. The company had a trading volume of 202,558 shares. The firm has a 50 day moving average price of $5.74 and a 200 day moving average price of $4.81. The company’s market cap is $153.26 million. Cytosorbents Corp has a 12 month low of $3.11 and a 12 month high of $8.10.

Cytosorbents Corp (OTCMKTS:CTSO) last released its earnings results on Tuesday, August 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.03. The business earned $1.90 million during the quarter, compared to analysts’ expectations of $2.18 million. Analysts predict that Cytosorbents Corp will post ($0.39) earnings per share for the current year.

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Cytosorbents Corp by 1.0% in the second quarter. Vanguard Group Inc. now owns 537,707 shares of the company’s stock valued at $2,447,000 after buying an additional 5,446 shares during the period. BlackRock Fund Advisors increased its stake in shares of Cytosorbents Corp by 39.3% in the second quarter. BlackRock Fund Advisors now owns 53,915 shares of the company’s stock valued at $245,000 after buying an additional 15,203 shares during the period. Douglass Winthrop Advisors LLC bought a new stake in shares of Cytosorbents Corp during the second quarter valued at about $321,000. Raymond James & Associates increased its stake in shares of Cytosorbents Corp by 318.6% in the second quarter. Raymond James & Associates now owns 324,603 shares of the company’s stock valued at $1,477,000 after buying an additional 247,052 shares during the period. Finally, Advisor Group Inc. bought a new stake in shares of Cytosorbents Corp during the second quarter valued at about $1,372,000.

About Cytosorbents Corp

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Receive News & Stock Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related stocks with our FREE daily email newsletter.